A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction-Reference-Cited by-同舟云学术

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction

Published:2013-12-09 Issue:5 Volume:15 Page:301-310
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Baril J¹,Conway B²,Giguère P³,Ferko N⁴,Hollmann S⁴,Angel JB³

Affiliation:

1. Hospital of the University of Montreal; Montréal QC Canada

2. The University of British Columbia; Vancouver BC Canada

3. Ottawa Hospital Research Institute; Ottawa ON Canada

4. Cornerstone Research Group; Burlington ON Canada

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference30 articles.

1. Antiretroviral treatment of adult HIV infection. 2012 recommendations on the international antiviral society - USA Panel;Thompson;JAMA,2012

2. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

3. Unboosted Atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen;Ghosn;Antivir Ther,2010

4. A review of low-dose ritonavir in protease inhibitor combination therapy;Cooper;Clin Infect Dis,2003

5. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-1 infected patients;Iloeje;HIV Med,2005

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects

;Drug Design, Development and Therapy;2019-07

2. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy;AIDS;2019-06-01

3. PharmGKB summary;Pharmacogenetics and Genomics;2018-05

4. Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials;Scientific Reports;2018-03-27

5. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemia;HIV Medicine;2017-07-03